Sarepta Therapeutics Posts $331M Q1 Profit, $730.8M Revenue Beat But Elevidys Demand Slumps
SRPT•Sarepta Therapeutics reported Q1 net income of $331 million and adjusted earnings of $3.16 per share, beating consensus estimates of $0.90. The company generated revenue of $730.8 million versus $467.9 million forecast, but weaker-than-expected Elevidys demand weighed on investor sentiment.
1. Q1 Earnings Beat Expectations
Sarepta reported net income of $331 million for the first quarter, translating to GAAP earnings of $2.88 per share. Adjusted earnings rose to $3.16 per share, significantly surpassing the $0.90 analysts had projected.
2. Revenue Performance
The company posted $730.8 million in Q1 revenue, topping the $467.9 million consensus forecast and reflecting strong sales growth year-over-year. This marks a substantial increase compared with the prior-year quarter.
3. Elevidys Uptake Concerns
Despite overall beat, Elevidys prescriptions grew more slowly than anticipated, prompting investor concern over future revenue contributions. Market reaction was muted as stakeholders await clearer adoption trends for the therapy.
